trending Market Intelligence /marketintelligence/en/news-insights/trending/2G9JfLGwcA5pERCUatCoZQ2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

In This List

Bellicum Pharmaceuticals prices offerings to raise nearly $140M

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

The Market Intelligence Platform

Bellicum Pharmaceuticals prices offerings to raise nearly $140M

Bellicum Pharmaceuticals Inc. priced an underwritten offering of preferred stock and warrants to raise about $57.5 million, and said concluded agreements for a further $70 million from certain institutional investors which will net $12.1 million immediately.

The Houston-based immunotherapy developer will sell 575,000 series 1 preferred stock at $100 each to raise the $57.5 million. Each preferred stock will come bundled with a warrant to buy 100 shares of the company.

The offering is expected to close by Aug. 21 with Jefferies and Wells Fargo Securities serving as book-running managers while Ladenburg Thalmann serving as co-manager.

Meanwhile, certain institutional investors have agreed to buy series 2 and series 3 preferred stock of the company for $70 million, but at a later date. The investors have agreed to pay $12.1 million to Bellicum for the option to buy the securities, separate from the $70 million they agreed to invest.

The amounts raised will help the company advance its immunotherapies for treating blood cancers, solid tumors and orphan inherited blood disorders. The company has a chimeric antigen receptor T cell, or CAR-T, therapy called BPX-601 which has shown promise in patients with advanced pancreatic cancer.